The Pharma Data

APRIL 7, 2022

“We’re continuing to grow our pipeline – through our own research-and-development efforts, such as our investigational RSV vaccine programs, as well as strategic investments in companies like ReViral – with a focus on end-to-end capabilities to help protect patients from severe illness, hospitalization, and death.”.

Virus 52

Virus Vaccine Clinical Development Hospitals 52

The Pharma Data

OCTOBER 25, 2020

SQI is accelerating the clinical development of its direct-to-consumer COVID-19 HOME Antibody Test, its COVID-19 RALI-dx Severity Triage Test and its COVID-19 RALI- fast Severity Triage Point-of-Care (POC) Test. FDA that Emergency Use Authorization (EUA) submission is acceptable for all three COVID diagnostic tests.

FDA 52

FDA Hospitals Clinical Development FDA Approval 52

Drug Target Review

FEBRUARY 1, 2024

In other cases, well-established biomarker profiles enable patient enrichment strategies in early-stage clinical development. Our subsidiary company leverages our neuroscience expertise and our mid- to late-stage clinical development expertise. We have a dedicated team of people who are executing against GRIN every day.

Therapies 104

Therapies Drug Development Disease Clinical Development 104

Drug Target Review

OCTOBER 1, 2024

I have worked in hospitals for many years and have always been committed to treating my patients in body and spirit with passion and enthusiasm. After a long career in the clinical hospital setting, where she mainly dealt with patients affected by solid tumours, she joined holding roles of increasing responsibility.

Doctors 97

Doctors Therapies Science Pharma Companies 97

The Pharma Data

FEBRUARY 24, 2022

– Jardiance is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death and hospitalization for heart failure, regardless of ejection fraction. heart failure is a leading cause of hospitalization and is becoming increasingly prevalent due to the aging population.

FDA Approval 52

FDA Approval FDA Hospitals Trials 52

The Pharma Data

MARCH 8, 2021

Phase 2a study enrolled 202 non-hospitalized adults who had signs or symptoms of COVID-19 within 7 days and confirmed active SARS-CoV-2 infection. Findings from the primary efficacy and safety endpoints and additional secondary objectives will be presented at an upcoming medical meeting. This press release features multimedia.

Trials 69

Trials Virus RNA Research Laboratories 69

The Pharma Data

JULY 12, 2021

The data were presented during the late-breaking clinical trials session at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). In addition, Merck plans to initiate a clinical program to evaluate molnupiravir for post-exposure prophylaxis in the second half of 2021. “It

Clinical Trials 52

Clinical Trials Laboratories Research Laboratories RNA 52

Drug Target Review

DECEMBER 28, 2023

Involving more than 250 investigators based at 19 hospital sites across the UK, the study has analysed genetic signatures in lung tumours, tracking how they have evolved over the past nine years in more than 815 patients.

Bioinformatics 105

Bioinformatics Immune Response DNA Vaccine 105

The Pharma Data

DECEMBER 9, 2020

The CARES study is focused on hospitalized patients with invasive candidiasis caused by the multidrug-resistant Candida auris organism, which is associated with high mortality. JERSEY CITY, N.J., 1) L iposomal IV formulation of ibrexafungerp entering Phase 1 study. President and Chief Executive Officer of SCYNEXIS.

Hospitals 52

Hospitals Pharmacokinetics Treatment Trials 52

The Pharma Data

OCTOBER 26, 2020

AR-711 is currently being developed as an inhaled, self-administered treatment for non-hospitalized patients suffering from mild to moderate COVID-19. AR-301 is a fully human IgG1 mAb currently in Phase 3 clinical development targeting gram-positive Staphylococcus aureus ( S. About Aridis Pharmaceuticals, Inc.

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

The Pharma Data

SEPTEMBER 11, 2020

Starpharma strived to release DEP remdesivir to allow for less frequent dosing and for use in non-hospital settings such as care homes. DEP remdesivir enables subcutaneous or under the skin injections rather than intravenous infusion, allowing for outpatient treatments and reducing the burden on hospitals.

Clinical Trials 52

Clinical Trials Pharma Companies Trials Hospitals 52

The Pharma Data

JUNE 2, 2022

A 30-plus valent pneumococcal candidate vaccine is also in pre-clinical development. “Affinivax grew out of our founders’ scientific and personal vision to drive vaccine innovation to make a meaningful impact on people’s lives, in both developed and developing countries,” said Steven Brugger, CEO of Affinivax, Inc.

Vaccine 52

Vaccine Immune Response Clinical Trials Disease 52

The Pharma Data

MAY 31, 2022

A 30-plus valent pneumococcal candidate vaccine is also in pre-clinical development. Affinivax grew out of our founders’ scientific and personal vision to drive vaccine innovation to make a meaningful impact on people’s lives, in both developed and developing countries,” said Steven Brugger, CEO of Affinivax, Inc.

Vaccine 52

Vaccine Immune Response Clinical Trials Disease 52

The Pharma Data

NOVEMBER 5, 2021

– In a new sub-analysis of the landmark EMPEROR-Preserved® phase III trial, Jardiance reduced the combined relative risk of cardiovascular death and hospitalization for heart failure and slowed kidney function decline – Jardiance consistently improved outcomes across the full range of kidney function down to an eGFR of 20 mL/min/1.73

Disease 52

Disease Hospitals Trials FDA 52

Drug Target Review

OCTOBER 16, 2024

It’s an exciting process—anticipating development risks, predicting outcomes, and aligning these with the greater vision of medical advancement. The true joy comes from navigating these complexities and asking the right questions early on, because these foundational steps are critical to the success of any clinical development process.

Clinical Development 52

Clinical Development Drug Development Therapies Disease 52

Cytel

FEBRUARY 20, 2024

Negative binomial probability distribution can be used to model the number of times a particular outcome occurs during a clinical trial.

Clinical Trials 59

Clinical Trials Hospitals Trials Therapies 59

The Premier Consulting Blog

NOVEMBER 20, 2023

Food and Drug Administration (FDA) made public a potentially game-changing proposal concerning the regulatory framework for laboratory-developed tests (LDTs). Understanding the nuances and implications of these changes is paramount for specialists in regulatory affairs and the clinical development arena. billion each year.

Laboratories 52

Laboratories Clinical Development FDA Regulations 52

The Pharma Data

NOVEMBER 18, 2020

The UK team of NeoDynamics has managed to introduce physicians at key centres to the new pulse biopsy system, despite the difficulties to accessing hospitals and key staff following the pandemic. The information in this press release is information that NeoDynamics is obliged to make public pursuant to the EU Market Abuse Regulation.

Hospitals 52

Hospitals Clinical Development Treatment Regulations 52

The Pharma Data

DECEMBER 13, 2020

Zhang completed his postdoctoral fellowship at Harvard Medical School/Boston Children’s Hospital. Dr. Kehua Fan has over 15 years of Business Development, Clinical Development of innovative drugs and other healthcare industry experience with MNCs and biotech companies. He received his B.S.

Medical Schools 40

Medical Schools Clinical Development Therapies RNA 40

The Pharma Data

JANUARY 26, 2021

As CMO, Dr. Short will be responsible for overseeing the clinical development of VarmX’s pipeline, including progression of its lead product, VMX-C001, into clinical proof of concept and registrational studies. Gerard Short, MBBS, as Chief Medical Officer (CMO). Dr. Short received his Bachelor of Medicine (MBBS) degree from St.

Clinical Development 40

Clinical Development Medical Schools Therapies Pharmaceuticals 40

The Pharma Data

APRIL 4, 2022

The high rate of unvaccinated people will continue to put a strain on hospitals and healthcare systems around the world, furthering the need for effective treatments for patients hospitalised with COVID-19,” said Levi Garraway, M.D., Chief Medical Officer and Head of Global Product Development, Roche. A decision on U.S.

Treatment 52

Treatment FDA Approval Clinical Trials FDA 52

The Pharma Data

AUGUST 31, 2021

Teva will continue to lead the clinical development and regulatory process and be responsible for commercialization of this candidate treatment, with MedinCell eligible for development milestones, royalties on net sales and future commercial milestones. Source link: [link].

FDA 52

FDA Treatment Drugs Hospitals 52

The Pharma Data

NOVEMBER 12, 2020

As part of an extensive clinical development programme, AstraZeneca and Acerta Pharma are currently evaluating Calquence in more than 20 company-sponsored clinical trials. Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. CALAVI US). Available online.

Trials 52

Trials Clinical Trials Immune Response FDA Approval 52

The Pharma Data

OCTOBER 18, 2020

Dr. Berk, commented “I am excited to join the Board of Inflection Biosciences as it advances its novel PIM/PI3K inhibitor, IBL-202, towards clinical development for unmet needs in B-cell malignancies and other cancers.”. Dr. Berk most recently has served as a consultant to several companies developing oncology therapies.

Small Molecule 40

Small Molecule Clinical Development Clinical Trials Licensing 40

The Pharma Data

JANUARY 20, 2021

The approval of Verquvo by the FDA, which is the first treatment for chronic heart failure approved specifically for patients following a hospitalization for heart failure or need for outpatient IV diuretics, is based on the results of the pivotal Phase 3 VICTORIA trial and follows a priority regulatory review. Verquvo (vericiguat) 2.5

FDA Approval 52

FDA Approval FDA Hospitals Treatment 52

The Pharma Data

JULY 8, 2021

Heart failure is a leading cause of hospitalization and is becoming increasingly prevalent in Western countries due to aging populations. Heart failure is a leading cause of hospitalization and is becoming increasingly prevalent in Western countries due to aging populations. vice president, Product Development, Lilly.

Trials 52

Trials Doctors Hospitals Clinical Trials 52

The Pharma Data

MAY 26, 2023

Food and Drug Administration (FDA) approved PAXLOVID™ (nirmatrelvir tablets and ritonavir tablets) for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death. PAXLOVID has been available in the U.S. 11) At this time, the U.S.

FDA Approval 40

FDA Approval FDA Hospitals Vaccine 40

The Pharma Data

DECEMBER 21, 2020

The FOCUS trial is Ultimovacs’ fourth Phase II clinical trial with UV1 and comes in addition to the collaboration Phase II trial announced in May 2020. “We To date, UV1 has been tested in four phase I clinical trials in a total of 82 patients and maintained a positive safety and tolerability profile as well as encouraging signals of efficacy.

Vaccine 52

Vaccine Trials Clinical Trials Clinical Development 52

The Pharma Data

SEPTEMBER 11, 2021

The decision is based on results from the landmark EMPEROR-Preserved phase III trial, in which Jardiance demonstrated a 21% relative risk reduction for the composite primary endpoint of cardiovascular death or hospitalization for heart failure in adults with heart failure with preserved ejection fraction compared with placebo.

Therapies 52

Therapies FDA Hospitals FDA Approval 52

The Pharma Data

JANUARY 25, 2021

agree to place handheld Ceribell Rapid Response EEG systems in hospitals in connection with its Phase 3 RSE clinical trial. Cessation will be measured and determined by clinical and EEG findings. hospitals participating in its study. Approximately 80 study sites in hospitals across the U.S. 26, 2021 12:01 UTC.

Clinical Trials 40

Clinical Trials Trials Hospitals Pharmaceutical Companies 40

The Pharma Data

JUNE 28, 2021

It was studied specifically in patients who have experienced a recent worsening heart failure event, meaning a recent hospitalization for heart failure or the use of intravenous diuretics, in order to reduce the risk of further worsening events. Vericiguat is the first sGC stimulator to be approved for the treatment of chronic heart failure.

Treatment 52

Treatment Clinical Trials Disease Clinical Development 52

The Pharma Data

DECEMBER 14, 2020

Specifically, it is being examined in adults who are hospitalized with COVID-19. “With the clinical program at AbbVie now underway, we are in a position to contribute a new therapeutic option to address this pandemic.” ” Under the license agreement, the development of ABBV-47D11 will be greatly advanced.

Licensing 52

Licensing Licensing Pharmacokinetics Clinical Trials 52

The Pharma Data

OCTOBER 19, 2020

She is executive medical director of immunology clinical development for the pharmaceutical company AbbVie in North Chicago, Ill. “Upadacitinib has shown superiority to one of the current standard-of-care treatment options in the clinic for these difficult-to-treat patients,” Pangan said. ” Rinvoq received U.S.

Clinical Trials 52

Clinical Trials Drugs Trials Treatment 52

The Pharma Data

JANUARY 27, 2021

As a clinician, healthcare administrator, biotech entrepreneur and venture capital investor, Steve’s leadership and breadth of experience in the clinical development of cell and gene therapies will be invaluable to PlateletBio as we progress our cell therapy platform into the clinic later this year,” said Sam Rasty, Ph.D.,

Therapies 40

Therapies Engineering Clinical Development Disease 40

The Pharma Data

NOVEMBER 1, 2020

In view of the importance and urgency, scientific teams at the Harvard Medical School, Santa Casa de Misericórdia de Santos Hospital (Jabaquara, Santos, Brazil) and at Tiziana are closely collaborating to facilitate initiation of this study in expedited time frames. NEW YORK and LONDON, Nov.

Clinical Trials 40

Clinical Trials Trials Medical Schools Hospitals 40

The Pharma Data

OCTOBER 25, 2020

Agitation associated with delirium is commonly seen in numerous hospital settings, resulting in serious medical complications and extended hospital stays. About Agitation Associated with Delirium: Delirium is a serious condition that occurs in a variety of hospital settings, including frequently in the intensive care unit.

Treatment 40

Treatment Trials FDA Hospitals 40

The Pharma Data

MARCH 23, 2021

Chief, Department of Head and Neck Medical Oncology, National Cancer Center Hospital East. We have the passion and determination to develop innovative medicines that help improve and extend the lives of people living with cancer. About Oncology at Bayer.

Treatment 52

Treatment Clinical Trials Trials Clinical Development 52